Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil, quantity: 500 microgram/ml - injection, solution - excipient ingredients: ethanol - indications as at 14 january 1994: prostin vr sterile solution (alprostadil) is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, mitral atresia, or transposition of the great vessels with or without other defects. prostin vr should be administered only by medically trained personnel in facilities in which paediatric patients can receive or have access to paediatric intensive care.

Australia - English - Department of Health (Therapeutic Goods Administration)

biotronik australia pty ltd - 35852 - defibrillator, implantable, automatic - a single chamber, rate adaptive icd with home monitoring functions, max. shock energy 40j and df4/is-1 connector. biocompatible titanium housing is hermetically sealed and serves as a potential antipole during shock delivery or in the case of unipolar lead configuration. ellipsoid shape facilitates implantation in the pectoral muscle area. the connections for bipolar pacing, sensing and shock delivery are in the header. dx functionality also senses in the right atrium. mr conditional. rivacor 7 vr-t dx belongs to a family of implantable cardioverter-defibrillators (icd). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias with ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: ?termination of spontaneous ventricular fibrillation (vf) through shock delivery ?termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffec

Australia - English - Department of Health (Therapeutic Goods Administration)

biotronik australia pty ltd - 35852 - defibrillator, implantable, automatic - a single chamber, rate adaptive icd with home monitoring functions, max. shock energy 40j and df4/is-1 connector. biocompatible titanium housing is hermetically sealed and serves as a potential antipole during shock delivery or in the case of unipolar lead configuration. ellipsoid shape facilitates implantation in the pectoral muscle area. the connections for bipolar pacing, sensing and shock delivery are in the header. dx functionality also senses in the right atrium. mr conditional. rivacor 5 vr-t dx belongs to a family of implantable cardioverter-defibrillators (icd). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias with ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: ?termination of spontaneous ventricular fibrillation (vf) through shock delivery ?termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffe

Australia - English - Department of Health (Therapeutic Goods Administration)

biotronik australia pty ltd - 35852 - defibrillator, implantable, automatic - a single chamber, rate adaptive icd with home monitoring functions, max. shock energy 40j and df4 connector. biocompatible titanium housing is hermetically sealed and serves as a potential antipole during shock delivery or in the case of unipolar lead configuration. the ellipsoid shape facilitates implantation in the pectoral muscle area. the connections for bipolar pacing, sensing and shock delivery are found in the device header. mr conditional. rivacor 7 vr-t belongs to a family of implantable cardioverter-defibrillators (icds). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias with ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: ?termination of spontaneous ventricular fibrillation (vf) through shock delivery ?termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffective atp or hemodynamically not tolerate

Australia - English - Department of Health (Therapeutic Goods Administration)

biotronik australia pty ltd - 35852 - defibrillator, implantable, automatic - a single chamber, rate adaptive icd with home monitoring functions, max. shock energy 40j and df4 connector. biocompatible titanium housing is hermetically sealed and serves as a potential antipole during shock delivery or in the case of unipolar lead configuration. the ellipsoid shape facilitates implantation in the pectoral muscle area. the connections for bipolar pacing, sensing and shock delivery are found in the device header. mr conditional. rivacor 5 vr-t belongs to a family of implantable cardioverter-defibrillators (icds). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias with ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: ?termination of spontaneous ventricular fibrillation (vf) through shock delivery ?termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffective atp or hemodynamically not tolerate

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil -

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - alprostadil - injection - 0.5 mg/ml - alprostadil 0.5 mg/ml

Philippines - English - FDA (Food And Drug Administration)

chemvet products, inc. - gentamicin ( as sulfate) (vet.) - solution for injection (im) - 100 mg per ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - alprostadil 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: alprostadil 0.5 mg/ml excipient: ethanol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - alprostadil - solution for infusion - 500microgram/1ml